hotspot -WSS

hotspot

author：Wikipedia 2025-10-01 01:49:46 - browse：49

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Trans patients at the end of life deserve respect and dignity

WSS

Abortion clinic in Cancun will cater to Americans

FDA greenlights medical device to combat bladder issues

Intellia plays down concerns on accidental germline transmission

Listen: Vivek Ramaswamy's star turn & leaky drug data

How the drug

Vivek Ramaswamy made waves in the debate, much as in biotech

hotspot

hotspot

hotspot

Alkermes shareholders re

As obesity drug market grows, telehealth companies court payers

Wildfire smoke exposes gaps in outdoor worker protections

Free speech concerns arise in wake of journal editor Eisen's firing

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Meadows told special counsel he could not recall Trump ever declassifying Mar

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare will require more price transparency from hospitals

State Dept. review finds Biden bears some blame for Afghanistan failures

Abortion clinic in Cancun will cater to Americans

entertainment

CDC says it’s too soon to assess risk posed by Covid subvariant

Roche's accidental data boosts hopes for anti

Excited delirium, Elijah McClain, and emergency physicians

Just how powerful is the placebo effect?

UCSF medical school apologizes for unethical prisoner experiments

Biotech incubator Curie.Bio graduates its first startup

focus

focus

hotspot

hotspot